A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
(SUMMIT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new pill called JNJ-77242113 to see if it can better treat moderate-to-severe plaque psoriasis. The pill aims to calm the immune system, which helps reduce skin problems caused by psoriasis.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial. Specifically, if you are on medications targeting interleukin 17, interleukin 23, or tumor necrosis factor, you must stop them at least 12 weeks before starting the trial. Also, you should not take proton pump inhibitors within 1 week of starting the trial.
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JNJ-77242113 or placebo once daily for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-77242113
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University